Drug Profile
Research programme: haemoglobin conjugated therapeutics - Therapure Innovations
Alternative Names: TBI-303Latest Information Update: 05 Feb 2021
Price :
$50
*
At a glance
- Originator Hemosol BioPharma
- Developer Therapure Innovations
- Class Haemoglobins; Protein-drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes